关注
Hannah Jones
Hannah Jones
Certara Inc.
在 certara.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development
HM Jones, K Rowland‐Yeo
CPT: pharmacometrics & systems pharmacology 2 (8), 1-12, 2013
6122013
Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective
HM Jones, Y Chen, C Gibson, T Heimbach, N Parrott, SA Peters, ...
Clinical Pharmacology & Therapeutics 97 (3), 247-262, 2015
4642015
A novel strategy for physiologically based predictions of human pharmacokinetics
HM Jones, N Parrott, K Jorga, T Lavé
Clinical pharmacokinetics 45, 511-542, 2006
3942006
Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches
NA Hosea, WT Collard, S Cole, TS Maurer, RX Fang, H Jones, SM Kakar, ...
The Journal of Clinical Pharmacology 49 (5), 513-533, 2009
3062009
Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data
HM Jones, HA Barton, Y Lai, Y Bi, E Kimoto, S Kempshall, SC Tate, ...
Drug Metabolism and Disposition 40 (5), 1007-1017, 2012
2632012
Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit
PV Fish, P Filippakopoulos, G Bish, PE Brennan, ME Bunnage, AS Cook, ...
Journal of medicinal chemistry 55 (22), 9831-9837, 2012
2532012
Modelling and PBPK simulation in drug discovery
HM Jones, IB Gardner, KJ Watson
The AAPS journal 11, 155-166, 2009
2242009
Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations
HM Jones, JB Houston
Drug Metabolism and Disposition 32 (9), 973-982, 2004
2172004
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based …
P Poulin, RDO Jones, HM Jones, CR Gibson, M Rowland, JY Chien, ...
Journal of pharmaceutical sciences 100 (10), 4127-4157, 2011
2152011
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance
BJ Ring, JY Chien, KK Adkison, HM Jones, M Rowland, RD Jones, ...
Journal of pharmaceutical sciences 100 (10), 4090-4110, 2011
1992011
Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling
HM Jones, N Parrott, G Ohlenbusch, T Lavé
Clinical pharmacokinetics 45, 1213-1226, 2006
1622006
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP™) predicts in vivo metabolic inhibition
A Rakhit, MP Pantze, S Fettner, HM Jones, JE Charoin, M Riek, BL Lum, ...
European journal of clinical pharmacology 64, 31-41, 2008
1342008
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution
R Do Jones, HM Jones, M Rowland, CR Gibson, JWT Yates, JY Chien, ...
Journal of pharmaceutical sciences 100 (10), 4074-4089, 2011
1322011
Dose selection based on physiologically based pharmacokinetic (PBPK) approaches
HM Jones, K Mayawala, P Poulin
The AAPS journal 15 (2), 377-387, 2013
1182013
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling
HM Jones, IB Gardner, WT Collard, PJ Stanley, P Oxley, NA Hosea, ...
Clinical pharmacokinetics 50, 331-347, 2011
1162011
Application of PBPK modelling in drug discovery and development at Pfizer
HM Jones, M Dickins, K Youdim, JR Gosset, NJ Attkins, TL Hay, IK Gurrell, ...
Xenobiotica 42 (1), 94-106, 2012
1132012
Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man
N Parrott, H Jones, N Paquereau, T Lavé
Basic & clinical pharmacology & toxicology 96 (3), 193-199, 2005
1062005
Maraviroc: in vitro assessment of drug–drug interaction potential
R Hyland, M Dickins, C Collins, H Jones, B Jones
British journal of clinical pharmacology 66 (4), 498-507, 2008
1032008
Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies
LB Avery, M Wang, MS Kavosi, A Joyce, JC Kurz, YY Fan, ME Dowty, ...
MAbs 8 (6), 1064-1078, 2016
832016
Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model
S Yamazaki, J Skaptason, D Romero, S Vekich, HM Jones, W Tan, ...
Drug metabolism and disposition 39 (3), 383-393, 2011
752011
系统目前无法执行此操作,请稍后再试。
文章 1–20